医薬品製造市場：製剤別、医薬品開発タイプ別、投与経路別、薬剤別、年齢層別、流通チャネル別、治療領域別-2024～2030年の世界予測

医薬品製造市場規模は2023年に6,206億8,000万米ドルと推定され、2024年には6,724億4,000万米ドルに達し、CAGR 8.66％で2030年には1兆1,101億7,000万米ドルに達すると予測されています。

医薬品製造は、ヒト用の医薬品と医薬品の研究、開発、生産、マーケティング、流通で構成されます。これらの製品は、様々な医療環境における疾病予防、診断、治療、管理を対象としています。主要エンドユーザーには、急性または慢性疾患の患者、医療専門家、臨床試験研究者、保険会社、規制機関などが含まれます。世界中で慢性疾患の有病率が高い高齢化人口が増加し、アンメット・メディカル・ニーズを対象とする先進医薬品へのニーズが高まっていることが、医薬品セグメントの成長に影響を与えています。また、政府からの資金援助が増加していることも、医療セグメントの研究開発活動を支援し、製薬会社の新薬開発を可能にしています。しかし、各国当局が課す厳しい規制要件や長い臨床試験プロセスが、新規製薬メーカーの参入障壁となっています。

さらに、ジェネリック医薬品やバイオシミラー医薬品との競合の激化や、強固なサプライチェーンの維持が大きな課題となっています。さらに、医薬品開発プロセスの技術的進歩や個別化医療への関心の高まりが、市場成長の持続的機会を生み出しています。また、研究開発プロセスを最適化するためのデジタル技術の導入により、医薬品開発効率が向上しています。

製剤：注射製剤の堅実な研究開発を支援するための投資急増

カプセルは、飲み込みやすさと正確な投与が可能なことから好まれています。カプセルは、即時放出型製剤にも徐放型製剤にも適しています。注射剤は、消化管吸収バリアをバイパスするため、迅速な作用発現と高い生物学的利用能を記載しています。これらは一般的に、救命薬、ワクチン、バイオ医薬品に使用されます。粉末剤は、錠剤やカプセルの嚥下が困難な患者に最適であり、必要に応じて便利な経口懸濁液や外用剤に再構成することができます。スプレー剤は、鼻腔や頬への投与など、局所的なドラッグデリバリーに適しています。吸収が早く、バイオアベイラビリティが高いため、緊急時の投薬に最適です。懸濁液は投与に柔軟性があり、固形剤の嚥下が困難な小児や高齢の患者に適しています。錠剤は、携帯性、製造の容易さ、費用対効果から、依然として最も人気のある剤形です。それぞれの剤形は、投与経路、作用発現時間、バイオアベイラビリティ、投与精度、使いやすさ、患者の嗜好などの要因に基づいて、特定の患者のニーズに対応しています。

医薬品開発タイプ：費用対効果から増加する外部委託医薬品製造

自社での医薬品開発は、製薬会社が研究開発、臨床試験、規制遵守、生産、マーケティング、流通のすべてを自社内で行うことを意味します。このアプローチを選択する企業は、多くの場合、包括的な研究開発施設と、医薬品開発プロセスのすべての側面を管理された環境で管理する熟練した人材を持っています。アウトソーシングでは、医薬品開発プロセスの様々な段階を円滑に進めるために、委託研究機関や製造機関などの外部組織と提携します。アウトソーシング・パートナーは、前臨床試験から市販後調査まで幅広いサービスを提供することができます。特定の医薬品開発段階に必要な施設や専門知識が不足している場合、企業はアウトソーシングを好みます。さらに、アウトソーシングは、サードパーティーベンダーの専門的な知識やリソースを活用することで、コストを抑制し、市場投入までの時間を短縮することができます。

投与経路：慢性疾患の増加に伴う非経口薬剤送達の研究開発の活発化

吸入ベースのドラッグデリバリーは、主に喘息、嚢胞性線維症、慢性閉塞性肺疾患などの呼吸器疾患の治療に好まれています。この経路では、作用発現が早く、標的肺への沈着により安全性が向上します。経口投与は、その投与のしやすさ、患者のコンプライアンス、剤形の柔軟性、費用対効果から、最も好まれる経路です。非経口ドラッグデリバリーには、静脈内注射（IV）、筋肉内注射（IM）、皮下注射（SC）などがあり、100％の生物学的利用能で迅速な作用発現が得られるため、緊急治療や糖尿病やがんなど長期的なケアが必要な慢性疾患に最適です。局所投与は特に、皮膚炎、乾癬、にきびなどの皮膚疾患の局所治療や、クリーム、ゲル、パッチなどを患部に直接塗布して痛みを緩和するのに適しています。

薬剤：一般用医薬品への傾斜

一般用医薬品（OTC）は、一般的な病気に対する効果的な治療法を消費者に提供するために不可欠です。アセトアミノフェンは広く使われている鎮痛剤で、頭痛、生理痛、腰痛、歯痛、関節炎など様々な症状において、軽度から中等度の痛みを和らげ、発熱を効果的に緩和します。サブサリチル酸ビスマスは、消化不良、胸やけ、吐き気、下痢などの一般的な胃腸障害の治療に使用される制酸・下痢止め薬です。デキストロメトルファン（DXM）は、脳の延髄領域における咳反射を一時的に緩和する咳止め薬です。ヒドロコルチゾンクリームは、炎症やかゆみを抑えることで、湿疹、皮膚炎、虫刺されなどの皮膚症状を治療するための局所用コルチコステロイドです。イブプロフェンは、頭痛、歯痛、月経痛、筋骨格系の損傷を緩和するために一般的に使用されます。プソイドエフェドリンは、多くの風邪薬に含まれる鼻の充血除去薬で、鼻腔の血管を狭め、腫れや粘液の蓄積を抑えることで鼻づまりを緩和します。処方薬は、薬剤師が調剤する前に医療専門家の承認が必要です。これらの薬は、安全な使用と最適な治療結果を確実にするために専門的な医療介入が必要な、より重篤な、または慢性的な症状に対して処方されることが多いです。アセトアミノフェン・プラス・ヒドロコドンは、中等度から重度の疼痛管理に使用されます。アムロジピンは血管を弛緩させて血流を改善する作用があり、高血圧症や狭心症によく処方されます。リシノプリルは血管を拡大し、血圧を下げ、高血圧治療に処方されます。メトホルミンは、食生活の改善や運動プログラムとともに、2型糖尿病の管理に処方されます。シンバスタチンはコレステロール値を下げ、心筋梗塞などの心血管障害のリスクを軽減します。

年齢層：高齢者の病状を治療する製剤のニーズが高い

成人は、高血圧、糖尿病、心血管疾患、精神疾患などの慢性疾患を管理するために薬剤を必要とします。最近の動向は、個人の遺伝的体質、ライフスタイル要因、環境の影響に対応する個別化医療の必要性が高まっていることを示しています。小児・青少年にとっては、学校での予防接種の義務や、はしかや水疱瘡などの小児疾患の予防のために、ワクチンが重要な役割を果たしています。さらに、小児の服薬アドヒアランスを確保するため、用量の正確性と嗜好性を考慮した小児用製剤が必要とされています。高齢者人口は、認知症、関節炎、骨粗鬆症などの慢性疾患に直面しています。薬剤療法は、薬剤間相互作用、副作用、腎機能と肝機能別の投与量調整を慎重に考慮した上で、年齢に適したものでなければなりません。薬剤療法のニーズや嗜好性に関して、様々な年齢層で医薬品製造の状況は異なります。成人の薬剤療法が個別化されたアプローチによる慢性疾患の管理に重点を置いているのに対し、小児用製剤はワクチン開発とアドヒアランスへの配慮に重点を置いています。高齢者人口では、加齢に伴う生理学的変化による薬剤相互作用や投与量の調整に特別な注意を払う必要があります。

流通チャネル：医薬品の非小売流通チャネルの普及

非小売流通チャネルは、主に病院、クリニック、政府機関、介護施設、その他の医療機関を対象としています。このセグメントでは、これらの施設内で治療を受ける患者の医療ニーズに対応するため、施設のバイヤーが医薬品を大量購入します。小売以外の流通が好まれるのは、小売チャネルでは容易に入手できなかったり、経済的に採算が合わなかったりする特殊な医薬品が必要とされるためです。小売流通は、オンラインとオフラインの薬局、スーパーマーケット、ドラッグストア、通信販売サービスを通じて、個人消費者に対応しています。一般用医薬品（OTC）、医療用医薬品、その他の医療製品を、迅速かつ簡便に調達できる小売流通を、顧客は頼りにしています。小売チャネルは、消費者に幅広い選択肢、競合価格、服薬カウンセリングや健康診断などの個別サービスを提供することを目的としています。非小売部門は、特殊な医薬品の大量注文を必要とする機関投資家に重点を置き、小売部門は、利便性、入手のしやすさ、多様な製品群を求める個人消費者に対応しています。

治療領域：新たながん治療法の開発に向けた技術革新の波

アレルギー疾患の世界の蔓延が、アレルギー治療や薬剤の必要性を高めています。高齢化人口の急増と不健康な生活習慣が心臓病の蔓延を助長しているため、心血管治療のニーズが高まっています。壊血病、皮膚炎、皮膚感染症などの皮膚科疾患の増加により、効率的な薬剤が必要とされています。糖尿病の増加により、効果的な治療が必要とされています。消化器疾患の増加は、消化器内科の治療と医薬品の進歩を必要とします。感染症は世界的に蔓延しており、ワクチンや抗ウイルス剤の継続的な開発が必要です。神経疾患の負担が増加しているため、薬剤や治療の改善が強く求められています。がんは依然として死傷者の主要原因であり、革新的ながん治療の必要性を高めています。人口の高齢化は眼疾患の蔓延を助長し、眼科治療の必要性を高めています。慢性疼痛は世界の負担となっており、効果的な鎮痛薬や非ステロイド性抗炎症薬が必要とされています。精神疾患は世界的に数100万人に影響を及ぼしており、精神医療における治療法のブレークスルーが必要とされています。慢性呼吸器疾患は、新規の肺治療の必要性に影響を及ぼしています。腎臓病は増加の一途をたどっており、革新的な腎治療が必要とされています。喘息やCOPDの症例は、呼吸器治療セグメントの進歩を必要としています。

地域別洞察

南北アメリカは、強力な研究開発能力、大手製薬企業の存在、有利な政府政策により、世界の医薬品市場において重要な地位を占めています。米国にはFDA認可の製造施設があり、生物製剤や複雑なジェネリック医薬品の製造に注力しています。ドイツ、フランス、スイス、英国などの欧州諸国には、革新的な製造技術を持つ先進的な製薬会社があります。これらのメーカーは、欧州医薬品庁が定める厳しい規制基準を遵守しながら、革新的な薬剤療法に多額の投資を行っています。アジア太平洋諸国のイニシアチブは、国内生産とイノベーションを促進することを目的としており、研究開発や高度な製造技術への投資を奨励しています。この政策により、製薬会社による新規特許出願が急増しています。さらに、アジア太平洋の民間と公的セクターによる医療への投資の増加が、医薬品製造産業に拍車をかけた。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスは医薬品製造市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を記載しています。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、医薬品製造市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、このセグメントの競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています。

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を記載しています。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を記載しています。

本レポートは、以下のような主要な質問に対応しています。

1.医薬品製造市場の市場規模と予測は？

2.医薬品製造市場の予測期間中に投資を検討すべき製品、用途は何か？

3.医薬品製造市場の技術動向と規制枠組みは？

4.医薬品製造市場における主要ベンダーの市場シェアは？

5.医薬品製造市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ワクチンと医薬品の世界の需要増加
    • 医薬品研究開発費の増加
    • 高齢者人口の増加と慢性疾患の発症率
  • 抑制要因
    • 医薬品製造に伴う高コストと複雑さ
  • 機会
    • 医薬品製造セクターにおける投資と資金調達プログラムの増加
    • 新しい医薬品製造技術の出現
  • 課題
    • 製薬会社に対する政府の厳しい規制
• 市場セグメンテーション分析
  • 製剤：注射剤の強力な研究開発を支援するための投資の急増
  • 医薬品開発タイプ：コスト効率の良さからアウトソーシング医薬品製造の利用が増加
  • 投与経路：慢性疾患の罹患率の上昇に伴い、非経口ドラッグデリバリーの研究開発活動が増加しています。
  • 薬剤：市販薬（OTC）への傾向
  • 年齢層：高齢者期の病状を治療するための薬剤処方に対する大きなニーズ
  • 流通チャネル：医薬品の非小売流通チャネルの浸透
  • 治療領域：新たな腫瘍治療法の開発に向けたイノベーションの波
• 市場動向分析
  • 南北アメリカにおける医薬品産業の繁栄と医薬品投資と輸出の急増
  • アジア太平洋における国内の医薬品製造に対する政府の支援的取り組みと投資
  • 新薬の研究開発に重点を置き、欧州、中東、アフリカ地域に大手製薬メーカーが進出
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ
  • 2022年に最も売れた処方薬と市販薬一覧

第6章 医薬品製造市場：製剤別

• イントロダクション
• カプセル
• 注射
• 粉末
• スプレー
• 懸濁液
• 錠剤

第7章 医薬品製造市場：医薬品開発タイプ別

• イントロダクション
• 社内
• アウトソーシング

第8章 医薬品製造市場：投与経路別

• イントロダクション
• 吸入
• 経口
• 非経口
• 局所

第9章 医薬品製造市場：薬剤別

• イントロダクション
• 市販薬
• 処方薬

第10章 医薬品製造市場：年齢層別

• イントロダクション
• 成人
• 幼児と青少年
• 高齢者

第11章 医薬品製造市場：流通チャネル別

• イントロダクション
• 非小売
• 小売

第12章 医薬品製造市場：治療領域別

• イントロダクション
• アレルギー
• 心血管疾患
• 皮膚科
• 糖尿病
• 消化器内科
• 感染症
• 神経学
• 腫瘍学
• 眼科
• 疼痛管理
• 精神医療
• 肺
• 腎臓病
• 呼吸器疾患

第13章 南北アメリカの医薬品製造市場：地域別

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第14章 アジア太平洋の医薬品製造市場：地域別

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第15章 欧州・中東・アフリカの医薬品製造市場：地域別

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第16章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析

第17章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PHARMACEUTICAL MANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PHARMACEUTICAL MANUFACTURING MARKET DYNAMICS
• FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
• FIGURE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 24. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 26. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 29. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 30. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SPRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IN-HOUSE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OUTSOURCE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INHALATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TOPICAL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OVER-THE-COUNTER (OTC) MEDICINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PRESCRIPTION MEDICINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ADULTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CHILDREN & ADOLESCENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GERIATRIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NON-RETAIL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RETAIL, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ALLERGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 70. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 71. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 72. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 73. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 74. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 75. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 76. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 77. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 78. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 79. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 80. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PSYCHIATRY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 81. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 82. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PULMONARY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 83. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 84. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RENAL DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 85. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 86. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 89. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 90. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 91. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 92. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 93. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 94. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 95. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 96. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 97. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 98. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 99. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 100. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 101. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 102. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 105. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 106. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 107. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 108. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 109. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 110. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 111. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 112. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 113. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 114. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 115. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 116. ARGENTINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 117. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 118. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 119. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 120. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 121. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 122. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 123. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 124. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 125. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 126. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 127. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 128. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 129. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 130. BRAZIL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 131. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 132. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 133. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 134. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 135. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 136. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 137. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 138. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 139. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 140. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 141. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 142. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 143. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 144. CANADA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 145. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 146. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 147. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 148. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 149. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 150. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 151. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 152. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 153. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 154. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 155. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 156. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 157. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 158. MEXICO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 159. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 160. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 161. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 162. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 163. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 164. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 165. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 166. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 167. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 168. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 169. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 170. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 171. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 172. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 173. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 174. UNITED STATES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 175. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 176. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 177. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 178. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 179. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 180. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 181. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 182. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 184. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 186. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 188. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 190. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 191. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 192. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 193. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 194. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 195. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 196. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 197. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 198. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 199. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 200. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 201. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 202. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 203. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 204. AUSTRALIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 205. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 206. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 207. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 208. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 209. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 210. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 211. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 212. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 213. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 214. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 215. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 216. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 217. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 218. CHINA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 219. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 220. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 221. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 222. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 223. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 224. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 225. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 226. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 227. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 228. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 229. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 230. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 231. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 232. INDIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 233. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 234. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 235. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 236. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 237. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 238. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 239. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 240. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 241. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 242. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 243. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 244. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 245. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 246. INDONESIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 247. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 248. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 249. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 250. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 251. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 252. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 253. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 254. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 255. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 256. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 257. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 258. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 259. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 260. JAPAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 261. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 262. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 263. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 264. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 265. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 266. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 267. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 268. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 269. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 270. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 271. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 272. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 273. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 274. MALAYSIA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 275. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 276. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 277. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 278. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 279. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 280. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 281. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 282. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 283. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 284. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 285. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 286. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 287. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 288. PHILIPPINES PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 289. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 290. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 291. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 292. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 293. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 294. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 295. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 296. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
• TABLE 297. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2018-2023 (USD MILLION)
• TABLE 298. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY AGE GROUP, 2024-2030 (USD MILLION)
• TABLE 299. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
• TABLE 300. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
• TABLE 301. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2018-2023 (USD MILLION)
• TABLE 302. SINGAPORE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPY AREA, 2024-2030 (USD MILLION)
• TABLE 303. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2018-2023 (USD MILLION)
• TABLE 304. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION, 2024-2030 (USD MILLION)
• TABLE 305. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2018-2023 (USD MILLION)
• TABLE 306. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT TYPE, 2024-2030 (USD MILLION)
• TABLE 307. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
• TABLE 308. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
• TABLE 309. SOUTH KOREA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
• TABLE 310. SOUTH KOREA PHARMACEUTICAL MA

[181 Pages Report] The Pharmaceutical Manufacturing Market size was estimated at USD 620.68 billion in 2023 and expected to reach USD 672.44 billion in 2024, at a CAGR 8.66% to reach USD 1,110.17 billion by 2030.

Pharmaceutical manufacturing comprises research, development, production, marketing, and distribution of drugs and medicinal products for human use. These products target disease prevention, diagnosis, treatment, and management in various healthcare settings. Key end-users include patients with acute or chronic illnesses, healthcare professionals, clinical trial researchers, insurance companies, and regulatory agencies. Rising aging populations with a higher prevalence of chronic diseases across the globe and increasing need for advanced medicines targeting unmet medical needs influence the growth in the pharmaceutical sector. In addition, rising government funding supports research and development activities in the healthcare sector, allowing new drug development for pharmaceutical companies. However, stringent regulatory requirements imposed by national authorities and the lengthy clinical trial processes create barriers to entry for new pharmaceutical manufacturers.

Moreover, increasing competition from generics and biosimilars and maintaining a robust supply chain pose significant challenges. Furthermore, the technological advancements in drug development processes and a growing focus on personalized medicine create sustainable opportunities for market growth. Also, embracing digital technologies to optimize R&D processes, enhancing the drug development efficiency

Formulation: Surging investment to support robust research and development of injectable formulations

Capsules are preferred for their ease of swallowing and accurate dosing capabilities. They are suitable for both immediate-release and extended-release formulations. Injectable formulations offer rapid onset of action and high bioavailability as they bypass gastrointestinal absorption barriers. These are commonly used for life-saving medications, vaccines, and biopharmaceutical products. Powders are ideal for patients with difficulty swallowing tablets and capsules; they can be reconstituted into convenient oral suspensions and topical applications when needed. Sprays are preferred for localized drug delivery, such as nasal and buccal administration. They offer rapid absorption and high bioavailability, making them ideal for emergency medications. Suspensions provide flexibility in dosing and are suitable for pediatric and senior patients who have difficulty swallowing solid dosage forms. Tablets remain the most popular dosage form due to their portability, ease of manufacturing, and cost-effectiveness. Each formulation type serves specific patient needs based on factors such as administration route, onset of action, bioavailability, dosing accuracy, ease of use, and patient preferences.

Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness

In-house drug development entails a pharmaceutical company conducting all research and development (R&D), clinical trials, regulatory compliance, production, marketing, and distribution within its organization. Companies that choose this approach often have comprehensive R&D facilities and skilled personnel to manage all aspects of the drug development process in a controlled environment. Outsourcing involves partnering with external organizations, such as contract research and manufacturing organizations, to facilitate various stages of the drug development process. Outsourcing partners may offer services ranging from preclinical studies to post-marketing surveillance. Companies prefer outsourcing if they lack the necessary facilities and expertise for specific drug development phases. Additionally, outsourcing can help control costs and reduce time-to-market by leveraging third-party vendors' specialized knowledge and resources.

Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease

Inhalation-based drug delivery is primarily preferred for treating respiratory disorders, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease. This route offers a rapid onset of action and improved safety due to targeted lung deposition. Oral administration is the most favored route due to its ease of administration, patient compliance, flexibility in dosage forms, and cost-effectiveness. Parenteral drug delivery includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections, offering rapid onset of action with 100% bioavailability, making it ideal for emergency treatments and chronic illnesses requiring long-term care, such as diabetes and cancer. Topical drug administration is particularly suitable for localized treatment of skin disorders such as dermatitis, psoriasis, and acne, and pain relief by applying creams, gels, and patches directly onto the affected area.

Drugs: Inclination toward Over-the-counter (OTC) drugs

Over-the-counter (OTC) drugs are vital in providing consumers with accessible and effective treatments for common ailments. Acetaminophen is a widely used analgesic and effectively relieves mild to moderate pain and alleviates fever in various conditions such as headaches, menstrual cramps, backaches, dental pain, and arthritis. Bismuth subsalicylate is an antacid and anti-diarrheal medication used to treat common gastrointestinal issues such as indigestion, heartburn, nausea, and diarrhea. Dextromethorphan (DXM) is a cough suppressant drug that temporarily relieves the cough reflex in the brain's medulla oblongata region. Hydrocortisone creams are topical corticosteroids designed to treat skin conditions, including eczema, dermatitis, and insect bites, by reducing inflammation and itching. Ibuprofen is commonly used to relieve headaches, dental pain, menstrual cramps, or musculoskeletal injuries. Pseudoephedrine is a nasal decongestant found in many cold medications and relieves congestion by narrowing blood vessels in the nasal passages and reducing swelling and mucus buildup. Prescription medicines require authorization from a healthcare professional before being dispensed by a pharmacist. These medications are often prescribed for more severe or chronic conditions where specialized medical intervention is necessary to ensure safe use and optimal therapeutic outcomes. Acetaminophen Plus Hydrocodone is used to manage moderate to severe pain. Amlodipine works by relaxing blood vessels and improving blood flow and is commonly prescribed for hypertension and angina. Lisinopril expands blood vessels, reduces blood pressure, and is prescribed for hypertension treatment. Metformin is prescribed for type 2 diabetes management alongside dietary changes and exercise programs. Simvastatin lowers cholesterol levels to reduce the risk of heart strokes and other cardiovascular problems.

Age Group: Significant need for drug formulations to treat geriatric medical conditions

Adults require medications for managing chronic conditions such as hypertension, diabetes, cardiovascular diseases, or mental health disorders. Recent trends indicate a growing need for personalized medicine that caters to individual genetic makeup, lifestyle factors, and environmental influences. For children & adolescents, vaccines play a vital role due to school immunization requirements and protection against childhood diseases, including measles or chickenpox. Additionally, there is a need for pediatric formulations that consider dosage accuracy and palatability to ensure medication adherence among children. The geriatric population faces chronic conditions such as dementia, arthritis, or osteoporosis. Medications must be age-appropriate with careful consideration of drug-drug interactions, side effects, and dosing adjustments based on renal and hepatic function. The pharmaceutical manufacturing landscape differs across various age groups regarding medication needs and preferences. While adult medications focus on managing chronic conditions with personalized approaches, pediatric formulations emphasize vaccine development and adherence considerations. Geriatric populations require special attention to drug interactions and dosage adjustments due to age-related physiological changes.

Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals

Non-retail distribution channels primarily cater to hospitals, clinics, government agencies, long-term care facilities, and other healthcare institutions. This segment involves bulk purchasing of pharmaceutical products by institutional buyers to meet the healthcare needs of patients receiving treatment within these establishments. The preference for non-retail distribution arises from the need for specialized medications that may not be readily available or economically viable through retail channels. Retail distribution caters to individual consumers through pharmacies both online and offline), supermarkets, drugstores, and mail-order services. Customers depend on retail distribution for over-the-counter (OTC) medications, prescription drugs, and other healthcare products that can be quickly and conveniently procured. Retail channels aim to offer consumers a wide range of options, competitive pricing, and personalized services such as medication counseling or health screenings. Non-retail focuses on institutional buyers that require bulk orders of specialized medications, while retail caters to individual consumers seeking convenience, accessibility, and a diverse product range.

Therapy Area: Wave of innovations toward development of new oncology treatment modalities

The increasing prevalence of allergic conditions worldwide drives the need for allergy treatment and drugs. The surge in aging populations and unhealthy lifestyles contributing to heart disease prevalence raises the need for cardiovascular therapies. The rise in a number of dermatology conditions, such as scurvy, dermatitis, and skin infections, necessitates efficient drugs. The rising diabetes epidemic creates a substantial need for effective therapies. Growth in gastrointestinal diseases necessitates advancements in gastroenterology treatments and medicines. Infectious diseases persist globally, requiring continuous vaccine and antiviral development. The rising burden of neurological disorders contributes to a significant need for improved drugs and therapeutics. Cancer remains a leading cause of casualties, driving the need for innovative oncology therapies. Aging populations contribute to increased eye disease prevalence and necessitate ophthalmic treatments. The global burden of chronic pain propels the need for effective analgesics or nonsteroidal anti-inflammatory drugs. Mental health disorders affect millions globally and require therapeutic breakthroughs within psychiatry. Chronic respiratory diseases influence the need for novel pulmonary treatments. The increasing prevalence of kidney disease requires innovative renal therapies. Cases of asthma and COPD necessitate advancements within the respiratory therapy area segment.

Regional Insights

The Americas hold a significant position in the global pharmaceutical market, attributed to its strong research & development (R&D) capabilities, presence of leading pharmaceutical companies, and favorable government policies. The United States has FDA-approved manufacturing facilities focusing on producing biologics and complex generics. European countries, including Germany, France, Switzerland, and the United Kingdom, have advanced pharmaceutical companies with innovative production technologies. These manufacturers have been investing heavily in innovative drug therapies while complying with stringent regulatory standards set by the European Medicines Agency. The Asia Pacific countries initiative aims to boost domestic production and innovation, encouraging investment in R&D and advanced manufacturing technologies. Their policies have led to a surge in new patents filed by pharmaceutical companies. Moreover, the rising investments in healthcare by the private and public sectors in the APAC region fueled the pharmaceutical manufacturing industry.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmaceutical Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmaceutical Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Actiza Pharmaceutical Pvt. Ltd., Advent Pharma Ltd., Aenova Group GmbH, Amgen Inc., AstraZeneca PLC, Asymchem, Inc., Azurity Pharmaceuticals, Inc., Bayer AG, Biocon Limited, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Famar Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Lonza Group AG, Lupin Limited, McKesson Corporation, Merck KGaA, Moderna, Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., Veranova, L.P., and Zeon Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Formulation
  • Capsules
  • Injectable
  • Powders
  • Sprays
  • Suspensions
  • Tablets

• Drug Development Type
  • In-House
  • Outsource

• Route of Administration
  • Inhalations
  • Oral
  • Parenteral
  • Topical

• Drugs
  • Over-the-Counter (OTC) Medicines
  • Prescription Medicines

• Age Group
  • Adults
  • Children & Adolescents
  • Geriatric

• Distribution Channel
  • Non-Retail
  • Retail

• Therapy Area
  • Allergy
  • Cardiovascular Diseases
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Infectious Disease
  • Neurology
  • Oncology
  • Ophthalmology
  • Pain Management
  • Psychiatry
  • Pulmonary
  • Renal Disease
  • Respiratory Diseases

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Pharmaceutical Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmaceutical Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Pharmaceutical Manufacturing Market?

4. What is the market share of the leading vendors in the Pharmaceutical Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Pharmaceutical Manufacturing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increase in global demand for vaccines and drugs
    • 5.1.1.2. Growing pharmaceutical R&D spending
    • 5.1.1.3. Growth in geriatric population and incidence rate of chronic disorders
  • 5.1.2. Restraints
    • 5.1.2.1. High costs and complexities associated with the pharma production
  • 5.1.3. Opportunities
    • 5.1.3.1. Rise in the investment and funding programs in the pharmaceutical manufacturing sector
    • 5.1.3.2. Emergence of novel pharmaceutical manufacturing technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent government regulations for pharmaceutical companies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Formulation: Surging investment to support robust research and development of injectable formulations
  • 5.2.2. Drug Development Type: Increasing use of outsourced pharmaceutical manufacturing due to its cost effectiveness
  • 5.2.3. Route of Administration: Rising research and development activities parenteral drug delivery with rising prevalence of chronic disease
  • 5.2.4. Drugs: Inclination toward Over-the-counter (OTC) drugs
  • 5.2.5. Age Group: Significant need for drug formulations to treat geriatric medical conditions
  • 5.2.6. Distribution Channel: Penetration of non-retail distribution channels for pharmaceuticals
  • 5.2.7. Therapy Area: Wave of innovations toward development of new oncology treatment modalities
• 5.3. Market Trend Analysis
  • 5.3.1. Flourishing pharmaceutical industry and burgeoning pharmaceutical investment & exports in the Americas
  • 5.3.2. Supportive government initiatives and investments for domestic pharmaceutical manufacturing in the Asia-Pacific
  • 5.3.3. Emphasis on R&D of novel drugs and presence of significant pharmaceutical manufacturers in the EMEA region
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis
• 5.8. Client Customization
  • 5.8.1. List of Top Selling Prescription and Over-the-Counter Drugs in 2022

6. Pharmaceutical Manufacturing Market, by Formulation

• 6.1. Introduction
• 6.2. Capsules
• 6.3. Injectable
• 6.4. Powders
• 6.5. Sprays
• 6.6. Suspensions
• 6.7. Tablets

7. Pharmaceutical Manufacturing Market, by Drug Development Type

• 7.1. Introduction
• 7.2. In-House
• 7.3. Outsource

8. Pharmaceutical Manufacturing Market, by Route of Administration

• 8.1. Introduction
• 8.2. Inhalations
• 8.3. Oral
• 8.4. Parenteral
• 8.5. Topical

9. Pharmaceutical Manufacturing Market, by Drugs

• 9.1. Introduction
• 9.2. Over-the-Counter (OTC) Medicines
• 9.3. Prescription Medicines

10. Pharmaceutical Manufacturing Market, by Age Group

• 10.1. Introduction
• 10.2. Adults
• 10.3. Children & Adolescents
• 10.4. Geriatric

11. Pharmaceutical Manufacturing Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Non-Retail
• 11.3. Retail

12. Pharmaceutical Manufacturing Market, by Therapy Area

• 12.1. Introduction
• 12.2. Allergy
• 12.3. Cardiovascular Diseases
• 12.4. Dermatology
• 12.5. Diabetes
• 12.6. Gastroenterology
• 12.7. Infectious Disease
• 12.8. Neurology
• 12.9. Oncology
• 12.10. Ophthalmology
• 12.11. Pain Management
• 12.12. Psychiatry
• 12.13. Pulmonary
• 12.14. Renal Disease
• 12.15. Respiratory Diseases

13. Americas Pharmaceutical Manufacturing Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Pharmaceutical Manufacturing Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Pharmaceutical Manufacturing Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. INR 15,000 Crore Proposed in Pharma Sector, India
  • 16.3.2. Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes
  • 16.3.3. Novo, Torrent may Widen Tie-Up
  • 16.3.4. U.S. FDA Approves Bristol Myers Squibb's Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
  • 16.3.5. Finnish Manufacturing Facility to Get EUR 50 Million Expansion
  • 16.3.6. Aenova and Galvita Enter Strategic Partnership
  • 16.3.7. Novo Nordisk Invests EUR 2.1 Billion in Hillerod Manufacturing Expansion
  • 16.3.8. Eli Lilly Adds USD 1.6 Billion to its Manufacturing Spending Plan in Indiana
  • 16.3.9. FDA Approves Novartis Millburn Facility for U.S. Commercial Production of Pluvicto
  • 16.3.10. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
  • 16.3.11. Pfizer Acquires Abzena's Biologic Manufacturing Facility

17. Competitive Portfolio

• 17.1. Key Company Profiles
• 17.2. Key Product Portfolio